Edgewise Therapeutics (EWTX) Price & Analysis

Compare

390 Followers

EWTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.60 - $38.12

Previous CloseN/A

Volume107.81K

Average Volume (3M)702.54K

Market Cap

$1.45B

Enterprise Value$1.66B

Total Cash (Recent Filing)$436.39M

Total Debt (Recent Filing)$4.56M

Price to Earnings (P/E)―

Beta2.29

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding105,200,220

10 Day Avg. Volume702,657

30 Day Avg. Volume702,543

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit3.16K

Enterprise Value/Ebitda-9.74

Forecast

1Y Price Target

$39.27

Price Target Upside188.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical Study SuccessThe updated MESA OLE data gives confidence as CANYON participants dosed with sevasemten for 18 months showed NSAA scores +0.8 from baseline versus a predicted natural history of -2.2.

Drug DevelopmentIn DMD, a 10 mg dose appears to have a profile that can move forward to Phase 3, encouraging further development.

Regulatory PathThe FDA has provided a clear path to registration for sevasemten in Becker muscular dystrophy.

Bears Say

Market UncertaintyThe likelihood of success for an accelerated approval approach in BMD is about 50/50 given the regulatory and political environment, which has become more uncertain in recent months.

Regulatory ChallengesThe FDA did not think EWTX's CANYON data alone was sufficient to support accelerated approval but provided clear and supportive feedback towards a traditional approval.

Edgewise Therapeutics News

Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

8d ago

ALB

3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

8d ago

HUT

BTDR

Edgewise Therapeutics initiated with a Strong Buy at Raymond James

Raymond James analyst Martin Auster initiated coverage of Edgewise Therapeutics (EWTX) with a Strong Buy rating and $46...

9d ago

EWTX

Edgewise Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $42 price target The clinical-stage...

1M ago

EWTX

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and...

1M ago

EWTX

Edgewise Therapeutics Announces Positive Sevasemten Results

Edgewise Therapeutics ( ($EWTX) ) has provided an announcement. On June 26, 2025, Edgewise Therapeutics announced positive results...

1M ago

EWTX

Morning Movers: Shell ticks higher after denying interest in BP deal

Stock futures are drifting cautiously higher as the S&P edges close to record highs. The dollar is under...

1M ago

Edgewise update in line with expectations, says Leerink

Edgewise Therapeutics (EWTX) announced that while the FDA deemed the CANYON data insufficient to support accelerated approval on...

1M ago

EWTX

Truist sees ‘slight weakness’ for Edgewise Therapeutics on regulatory feedback

Truist keeps a Buy rating with a $50 price target on Edgewise Therapeutics (EWTX) after the company’s updates...

1M ago

EWTX

Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges

Edgewise Therapeutics (EWTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

1M ago

EWTX

Edgewise drops 4% after FDA denies accelerated approval

Edgewise Therapeutics (EWTX) said this morning that the FDA deemed the CANYON data alone insufficient for an accelerated...

1M ago

EWTX

Edgewise Therapeutics announces results from sevasemten program

Edgewise Therapeutics (EWTX) unveiled results in its sevasemten program for Becker and Duchenne muscular dystrophies. The company announced...

1M ago

EWTX

Promising Developments in Edgewise Therapeutics’ Muscular Dystrophy Programs Drive Buy Rating

In a report released on May 8, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Edgewise...

3M ago

EWTX

Edgewise Therapeutics Reports Strong Q1 2025 Progress

Edgewise Therapeutics, Inc. ( ($EWTX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

EWTX

EWTX FAQ

What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?

Edgewise Therapeutics, Inc. lowest stock price was $10.60 and its highest was $38.12 in the past 12 months.

What is Edgewise Therapeutics, Inc.’s market cap?

Edgewise Therapeutics, Inc.’s market cap is $1.45B.

When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?

Edgewise Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 91 days.

How were Edgewise Therapeutics, Inc.’s earnings last quarter?

Edgewise Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.074.

Is Edgewise Therapeutics, Inc. overvalued?

According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edgewise Therapeutics, Inc. pay dividends?

Edgewise Therapeutics, Inc. does not currently pay dividends.

What is Edgewise Therapeutics, Inc.’s EPS estimate?

Edgewise Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Edgewise Therapeutics, Inc. have?

Edgewise Therapeutics, Inc. has 105,200,220 shares outstanding.

What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?

Edgewise Therapeutics, Inc. reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 1.24%.

Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?

Currently, no hedge funds are holding shares in EWTX

Edgewise Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.29%

Trailing 12-Months

Asset Growth

-17.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edgewise Therapeutics, Inc.

Edgewise Therapeutics (EWTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for rare muscle disorders. The company's primary aim is to address the unmet medical needs of patients with debilitating neuromuscular diseases by leveraging its proprietary drug discovery platform to develop novel, small molecule therapies. Edgewise's lead product candidates target specific genetic mutations and pathways involved in muscle dysfunction, offering potential therapeutic solutions for conditions such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

Edgewise Therapeutics (EWTX) Earnings & Revenues

Historic Earnings Reports

EWTX Stock 12 Month Forecast

Average Price Target

$39.27

▲(188.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,15.756923076923076,18.693846153846152,21.630769230769232,24.567692307692308,27.504615384615384,30.441538461538464,33.378461538461536,36.315384615384616,39.252307692307696,42.18923076923077,45.12615384615385,48.06307692307693,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,14.854615384615386,16.88923076923077,18.923846153846156,20.958461538461542,22.993076923076927,25.02769230769231,27.062307692307694,29.09692307692308,31.131538461538465,33.16615384615385,35.20076923076924,37.23538461538462,{"y":39.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.82,12.910769230769231,13.001538461538463,13.092307692307692,13.183076923076923,13.273846153846154,13.364615384615385,13.455384615384615,13.546153846153846,13.636923076923077,13.727692307692308,13.818461538461538,13.909230769230769,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.38,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >